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The skeleton is one of the most common sites of metastatic disease, affecting a large number of patients
with advanced cancer. Although an increasing number of therapies are available for treatment of bone
metastasis, this remains incurable, highlighting the need for better understanding of the underlying
biology. Metastatic tumour spread to distant organs is a multistage process, involving not only cancer
cells but also those of the surrounding host microenvironment. Tumour associated macrophages are
multifunctional cells that contribute both to tumour development and response to treatment by
regulating adaptive immunity, remodelling of stroma, mediating basement membrane breakdown and
angiogenesis. Although direct evidence for a speciﬁc role of macrophages in bone metastasis is limited,
their involvement in metastasis in general is well documented. In this review we provide an overview of
role of macrophages in tumour progression, with particular emphasis on their potential role in bone
metastasis.
& 2013 Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The skeleton is a common site of metastatic disease, affecting a
large number of patients with advanced cancer [1]. Around 70% of
patients who die of prostate and breast cancer concurrently
experience bone metastasis and the incidence in kidney, thyroid
and bronchus carcinomas reported to be around 30–40%. In
contrast, tumours of the gastrointestinal tract rarely metastasise
to the skeleton (∼5%) [2].
Metastasis to bone usually signiﬁes an increased morbidity due
to skeletal-related events, including bone pain, nerve and spinal
cord compression syndrome, hypercalcaemia and pathologic frac-
tures. As a result, the quality of life of the affected individuals may
be greatly diminished [1]. Despite signiﬁcant improvements in
the outcome of patients with organ-conﬁned cancer, patients with
metastatic disease have not shared the same advances [3]. In an
effort to maintain quality of life, improve survival as well as
increase therapeutic options available for patients with bone
metastasis, the underlying mechanisms should be investigated
and understood.
A number of complex steps are involved in the formation
of bone metastasis, involving a myriad of interactions between
different cell types in conjunction with a large number of soluble
factors, extracellular matrix components, hormones, physical
properties [3]. Increasing evidence suggest that macrophages
contribute both to primary tumour growth and to the subsequentlsevier GmbH. This is an open accdevelopment of metastasis [4]. However, there is very limited
evidence for a speciﬁc role of macrophages in development and
progression of bone metastasis. In this review we will give a brief
overview of the current understanding of the contribution of
macrophages to cancer metastasis, with particular emphasis on
the involvement in tumour spread to the skeleton.2. Macrophages
2.1. Macrophage classiﬁcation and subtypes
Macrophages differentiate in tissues from extravasating mono-
cytes and form an important component of the immune system
characterised by their multifunctional nature. Monocytes are
members of the family of leucocytes originating in the bone
marrow, and they share a common progenitor with eosinophils,
neutrophils and mast cells among others. Monocytes circulate for
several days in the bloodstream where they are ﬁrst released,
followed by their entry into tissues where they replenish the
tissue macrophage population [5].
Cells that belong to the monocyte/macrophage lineage are
deﬁned by their plasticity and heterogeneity, and their phenotype
can be altered and adapted according to their resident micro-
environment [6]. Macrophages are classiﬁed into M1 and M2
types, reﬂecting the Th1/Th2 nomenclature (see Fig. 1 and
Tables 1). M1, or classically activated macrophages, are promoted
by ‘classical activators’, such as interferon γ and lipopolysaccharide
[7]. They are characterised by high IL-23 and IL-12 production,
high capacity for antigen presentation and eventual activation ofess article under the CC BY-NC-ND license
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Fig. 1. Macrophage polarization. Exposure to different cytokine milieu promotes the differentiation of monocytes into polarised macrophage subsets. When exposed to LPS,
IFN-γ or other microbial products, monocytes differentiate into M1 macrophages. When exposed to IL-4, IL-10, IL-13 and immuno-suppressive agents, monocytes
differentiate into M2 macrophages. M1 and M2 subsets share different characteristics in their function and phenotype. M1 cells have bactericidal activity, immuno-
stimulatory functions and display tumour cytotoxicity. M2 cells promote tissue repair and angiogenesis and have high scavenging ability, favouring tumour progression.
Abbreviations are: RNI, reactive nitrogen intermediates; ROI, reactive oxygen intermediates; IL, interleukin; TNF, tumour necrosis factor; CXCL, chemokine (C-X-C motif)
ligand; IFN, interferon; LPS, lipopolysaccharide; IC, immune complexes; TLR, toll-like receptor; MR, mannose receptor; SR, scavenger receptor; CCL, CC chemokine ligand;
TGF, transforming growth factor.
Table 1
Characteristics of M1, M2 and TAM. Different macrophage phenotypes share different characteristics in terms of polarising signals, membrane receptors, cytokines and
chemokines released and function. The most commonly used markers for each macrophage type is given.
M1-classically activated macrophages M2-alternatively activated macrophages TAM-tumour-associated
macrophages
References
Polarising
signals
IFN-γ, LPS or TNF-a IL-4, IL-13 (M2a), IC+TLR/IL-1R Ligands (M2b), IL-10 (M2c) CSF-1, VEGF, CCL2/3/4/5/8,
IL-4, IL-13, IL-10, TGF-β, PGE2
[4,9,10]
Membrane
receptors
TLR2, TLR4, CD16, CD32, CD64, CD80,
CD86
Scavenge receptor A/B, CD 14, CD 23, CD 163, MR CD11b, CD45, F4/80 (mice),
CXCR4, Gr1,CD68, VEGFR
[4,9,10]
Cytokines
released
High IL-12, IL-23, low IL-10, IL-1, TNF, IL-
6, ROI, RNI
High IL-10, low IL-12; TGF-β (M2c); low IL-1, TNF, IL-6 (not
M2b); high decoy IL-1RII, IL-1R-antagonist, EGF, FGF, VEGF,
TNF-β
FGF, PDGF, EGFR, VEGF, ANG1/2,
IL-1/8, TNF-α, TP, MMP-2/9, CSF-1
[4,9,10]
Chemokines
released
CXCL 8/9/10/11/16 CCL2/3/4/5 CCL 1/16/17/18/22/24 CCL-2/3 [4,9,10]
Function Th2 responses, type II inﬂammation,
allergy, killing and encapsulation of
parasites
Th2 activation, immunoregulation, matrix deposition
and tissue remodelling
Angiogenesis, tumour growth,
tumour invasion, intravasation,
immunosuppression, metastasis
[4,9,10]
Markers
(mouse)
iNOS, CD197 Arginase-1, CD163 F4/80 [4,9,10]
Abbreviations are: IFN, interferon; LPS, lipopolysaccharide; TNF, tumour necrosis factor; IL, interleukin; IC, immune complexes; TLR, toll-like receptor; CSF, colony
stimulating factor; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor; CCL, CC chemokine ligand; TGF, transforming growth factor;
PGE, prostaglandin E; ROI, reactive oxygen intermediates; RNI, reactive nitrogen intermediates; EGF, epidermal growth factor; FGF, ﬁbroblast growth factor; PDGF, platelet-
derived growth factor; EGFR, epidermal growth factor receptor; ANG, angiopoietin; MMP, matrix metalloproteinase; CXCL, chemokine (C-X-C motif) ligand.
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well as towards cells that have ingested intracellular microorgan-
isms, is a key feature of M1 macrophages, mediated by the release
of TNF, nitric oxide and reactive oxygen intermediates [4]. The
involvement of M1 macrophages in the adaptive immune system
is highlighted by the production of copious amounts of proin-
ﬂammatory and immunomodulatory cytokines [9].
M2, or alternatively activated macrophages, are induced by
IL-4, IL-10 and or IL-13 [7]. M2 is a broad name given to several
forms of activated macrophages, excluding classic M1 cells, but
including cells exposed to IL-13 or IL-4, IL-10, immune complexes,serocosteroid hormones and glucocorticoid [10]. Their main char-
acteristics are suppression of inﬂammatory responses, poor anti-
gen capacity and stimulation of Th2 responses [8]. They have been
extensively shown to promote angiogenesis, wound healing and
tissue remodelling, as well as to scavenge debris [8]. M2 macro-
phages are further categorised into M2a, M2b and M2c subtypes,
depending on the environmental signals that deﬁne their activa-
tion. M2c is the most immunosuppressive of these phenotypes [9].
However, the different macrophage phenotypes are not considered
distinct entities due to the degree of overlap between them,
making their separation rather difﬁcult and tentative.
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Fig. 2. The role of tumour-associated macrophages in tumour progression. Chemotactic factors recruit macrophages to tumours, where they develop into tumour-associated
macrophages (TAMs) involved in a number of tumour-promoting activities that enhance tumour growth, progression and metastasis. TAMs preferentially migrate into
hypoxic areas of tumour where they express and secrete several factors (e.g. VEGF, PDGF, TNF-a, MMPs) that stimulate angiogenesis. Moreover, TAMs promote tumour
migration, invasion and intravasation via the production of proteolytic enzymes that break down the basement membrane and remodel the extracellular matrix. TAMs also
inhibit host immune responses against the tumour via the secretion of a range of immuno-modulatory growth factors and cytokines. Abbreviations are: M-CSF, macrophage
colony-stimulating factor; TGF, transforming growth factor; IL, interleukin; CCL, CC chemokine ligand; TNF, tumour necrosis factor; MMP, matrix metalloproteinase.
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Rudolf Virschow ﬁrst proposed an association between inﬂam-
mation and cancer in 1863, after observing the inﬁltration of
leucocytes in tumours [11], and this view is still supported by
today′s epidemiological, clinical and experimental studies [4]. The
microenvironment created by inﬂammation provides the ideal
conditions for neoplastic transformation and enhances the growth
of tumours [12]. The inﬂammatory tumour inﬁltrate comprises a
number of different cell types, including granulocytes, lymphoid
cells, mast cells, natural killer cells, dendritic cells and macro-
phages, the most abundant cell type, representing a signiﬁcant
regulator of the association between inﬂammation and cancer. In
breast cancer, macrophages may account for up to 50% of the
tumour cell mass [13].
Tumour-derived signals stimulate recruitment of monocytes
from the circulation that subsequently develop into tumour-
associated macrophages (TAMs) [14,15] (see Fig. 2). Molecules
such as platelet derived growth factor (PDGF), vascular endothelial
growth factor (VEGF), macrophage colony stimulating factor (M-
CSF) and transforming growth factor (TGFβ) are chemotactic for
macrophages and also stimulate their differentiation and survival
[4]. Numerous studies have reported that a large number of TAMs
indicates a poorer prognosis of human malignancies [16].
The phenotype and the function of differentiated mature TAMs
resembles the M2, rather than the M1, phenotype and hence
promote tumour growth, invasion and metastasis [4,9]. The main
characteristics of TAMS are poor capacity for antigen presentation,
low cytotoxicity for tumour cells, poor NO production and ability
to suppress T-cell proliferation [17]. One of the most signiﬁcant
features of TAMs is their capacity to directly promote tumour
growth through the initiation and progression of tumour angio-
genesis, facilitating the survival and metastatic spread of cancer
cells. Their involvement in these processes and how this isrelated to bone metastasis will be discussed in the following
sections.2.2.1. The role of tumour associated macrophages in angiogenesis
Angiogenesis, an M2-associated function [18], describes the
formation of new blood vessels from a pre-existing vascular
system [19]. It is a requirement for any tumour to grow to greater
than 2 mm in diameter, as it ensures adequate supply of nutrients
and oxygen required for tumour cell growth and provides an
effective way of removing waste products. Furthermore, angiogen-
esis provides an exit path for tumour cells into the bloodstream, a
fundamental step in the formation of clinically signiﬁcant metas-
tases [16]. TAMs are considered one of the most important
regulators of angiogenesis in tumours as they are involved in the
two crucial steps of the process; the development of new blood
vessels and their modelling into a comprehensive functional
network [14,19].
Pro- and anti-angiogenic factors secreted by tumour, stroma
and inﬂammatory cells all contribute to the regulation of angiogen-
esis [20]. Accumulation of TAMs has been linked to the production
of these factors, such as VEGF, TGFβ and PDGF, and consequently to
angiogenesis, in a number of cancer studies [8]. In human tumours,
TAMs have been shown to accumulate mainly in areas of poor
vascular supply and necrosis, as well as around blood vessels [16].
An association between the presence of an increased number of
macrophages and high vascularity has been described in breast
tumours, where lymph node involvement was greater in tumours
with higher number of TAMs when compared to tumours with
low TAM density [21]. This can provide a partial explanation for
the reported correlation between the inﬁltration of a high number
of TAMs and reduced overall survival in patients with primary
breast cancer [21]. A similar positive association is identiﬁed in
several other tumour types [14] including oesophageal squamous
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cancer [25].
A number of studies have reported that angiogenesis in solid
tumours is effectively stimulated by hypoxia, which has been
shown to control the release of pro-angiogenic factors by both
macrophages and tumour cells in vitro [19]. Different mechanisms
lead to hypoxia, with the most important being that the disorga-
nised nature of newly formed tumour blood vessels mean that
they are more likely to collapse [26]. If a tumour is growing at a
rate higher than that at which the new blood vessels are formed,
this may in turn contribute to development of further hypoxic
areas [27]. Co-culturing human monocytes with multicellular
breast cancer spheroids have indicated that monocytes show a
preference to accumulate around the central regions of necrosis, in
the inner, hypoxic cell layers [19]. In addition, hypoxia suppresses
the migration of macrophages, leading to the immobilisation of
TAMs in avascular, hypoxic and necrotic areas of tumours where
they appear to collaborate with tumour cells to promote angio-
genesis [17]. In breast carcinomas, TAMs express hypoxia-
inducible factor-1 (HIF-1) and HIF-2a in response to hypoxia,
which in turn promote the release of bFGF, CXCL8 and VEGF,
signiﬁcant stimulators of angiogenesis [17].
Macrophages are considered the main producers of VEGF, a
potent pro-angiogenic cytokine that is over-expressed in many
tumour types, including endometrial, ovarian, central nervous
system, breast and kidney cancers [28]. TAMs also contribute
to the production of other important angiogenic factors, such as
thymidine phosphorylase (TP), matrix metalloproteinases (MMPs),
urokinase plasminogen activator (uPA) and their level of expres-
sion correlates with angiogenesis and transition to invasive carci-
nomas [12,16,29–31]. Moreover, TAMs have been shown to play a
key role in the initiation of the ‘angiogenic switch’, a step in
tumour development essential for the transition of pre-invasive to
invasive, malignant lesions [32]. The expression by both TAMs
and tumour cells of MCP-1, a key regulator of macrophage
accumulation in tumours, is positively associated with the levels
of the angiogenic factors VEGF, TP and tumour necrosis factor
(TNF)-a [22].2.2.2. The role of tumour-associated macrophages in invasion,
intravasation and metastasis
The mechanism by which macrophages enhance tumour metas-
tasis is attributed to the paracrine loop that exists between EGF
and macrophage colony stimulating factor-1 (M-CSF-1 or CSF-1),
and involves interactions between macrophages and tumour cells.
The most important source of EGF in tumours is TAMs [12]. In a
number of different tumour types, overexpression of EGF receptor is
associated with poor prognosis and metastasis [33–35]. Tumour
cells produce CSF-1, which stimulate macrophages to express EGF,
which in turn stimulates the expression of CSF-1 by tumour cells
thereby creating a positive feedback loop. Disruption of this loop by
blocking either CSF-1 receptor signalling, or the EGF receptor, is
shown to be sufﬁcient for the inhibition of both macrophages and
breast cancer cell invasion and migration, leading to the inhibition
of metastasis [36]. Use of in vivo multiphoton microscopy has
revealed that metastasis is more frequent when mammary tumour
cells are found in close association with TAMs [37]. Intravasation,
the entry of tumour cells in blood vessels, is also stimulated by
macrophages, potentially through the paracrine loop operating
between EGF receptor signalling in macrophages and CSF-1 produc-
tion by tumour cells [38].
One of the most signiﬁcant processes associated with invasion
and metastasis of tumours is the activation of proteolytic enzymes,
leading to destruction of the basement membrane, a natural
barrier for the invasion of tumour cells [39]. Macrophages areimportant sources of proteolytic enzymes (uPA and MMPs, espe-
cially MMP-9 and MMP-7), thereby facilitating the escape of
cancer cells from the tumour mass and their invasion in the
systemic circulation where they may subsequently develop into
distant metastases [12].
TAMs have also been shown to directly promote tumour
metastasis [6], and early reports suggested that the development
of lung tumour nodules is signiﬁcantly increased by macrophages
[40]. Subsequently, a positive correlation has been demonstrated
in several tumour types between the macrophage content in the
primary tumour and the subsequent establishment of metastases
[14,21,23]. Systemic depletion of macrophages by silencing of CSF-
1 resulted in fewer lung metastases compared with the controls in
a transgenic mouse model of PyMT-induced mammary tumours,
suggesting that either TAMs or systemic macrophages play a
signiﬁcant role in the formation of distant metastasis [41]. A link
between the presence of macrophages in sites of metastasis and
the subsequent establishment of metastatic tumours has been
identiﬁed. Depletion of macrophages in the peritoneum limited
the capacity of tumour cells introduced into the portal vein to
survive and grow in the liver [42].
In breast cancer, macrophage density appears to be a more
effective predictor of survival when compared to nodal status,
again supporting the direct role of macrophages in tumour
progression [21]. A recent study provides convincing evidence
that breast tumour colonisation of lungs is regulated by macro-
phages. Using three different means of macrophage depletion, a
distinct macrophage population was shown to be required in the
different steps of metastasis, including extravasation, survival and
growth. In addition, the growth of pre-formed metastatic nodules
was also inhibited by the depletion of macrophages [43]. Never-
theless, this may vary with tumour type as the efﬁcacy of anti-
body therapy used for colorectal cancer was signiﬁcantly reduced
following the depletion of liver macrophages [44].
2.2.3. The role of tumour associated macrophages in
immunosuppression
Several lines of evidence support that TAMs have an immuno-
suppressive M2 phenotype [15], and the strategic locations of
these cells highlight their importance in regulating anti-tumour
immunity [8]. TAMs modulate the host immune response to
tumours via the increased expression of enzymes, chemokines
and cytokines that modulate the action of antigen-presenting
cells as well as the function of T and B cells [6]. TAMs generate
factors that prevent the inﬁltration of cells with anti-tumour
activities (e.g. cytotoxic T cells) as well as enhance the recruitment
of cells that inhibit immune responses (e.g. regulatory T cells) [6].
Overall, the evidence supports that TAMs are able to down-regulate
the normal immune response to tumour cells, thereby supporting
tumour growth and aiding metastatic spread.3. Bone metastasis
Bone metastasis is a multi-step process that takes place in the
later stages of tumour progression. Initial steps, all involving
macrophages, include the detachment of tumour cells from the
primary tumour and their invasion into the circulation. Once in the
circulation, tumour cells move towards the preferred target
tissues, such as bone, where they adhere to the endosteal surface
and form small tumour colonies [45]. The exact mechanism
driving the tumour cells to metastasise to bone remains to be
identiﬁed, but the various cell types (including macrophages),
extracellular matrix components and soluble factors present in the
bone microenvironment provide the ideal site for tumour cell
colonisation and survival [46]. During the development of cancer-
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tumour cell proliferation are secreted and activated, including
insulin-like growth factors (IGF) I and II, transforming growth
factor β (TGFβ), platelet-derived growth factors (PDGFs), ﬁbroblast
growth factors (FGFs), calcium and bone morphogenic proteins
(BPMs) [47]. Cancer cells in turn release factors that that stimulate
bone remodelling, therefore promoting the development of osteo-
blastic or osteolytic metastases [48].
3.1. The potential role of macrophages in bone metastasis
Although many of the studies mentioned so far have implicated
macrophages in promoting tumour metastasis to distant sites,
there is surprisingly little direct evidence supporting their speciﬁc
involvement in bone metastasis (see Tables 2). The following
sections will summarise our current understanding of macro-
phages in this process.
3.1.1. Clodronate-liposome depletion of macrophages in models of
bone metastasis
In order to establish whether macrophages are involved in the
development of bone metastasis, researchers have used pharmaco-
logical depletion agents. Administration of clodronate-liposomes in
mouse models causes macrophage depletion, resulting in signiﬁcant
inhibition of tumour angiogenesis and tumour growth [49]. The
ability of macrophages to phagocytose the liposome encapsulated
form enables the release of clodronate, promoting apoptosis. How-
ever, macrophages are unable to ingest free clodronate leading to its
rapid removal from the circulation [50]. Clodronate-liposomes are
shown to reduce survival of macrophages in vitro and the number of
monocytes in peripheral blood in vivo, and is therefore a widely used
research tool when studying the role of macrophages in biological
processes, including tumour progression [51].
Clodronate liposomes have been used to investigate the effect
of a reduced number of monocytes in the peripheral blood and
macrophages in the tumour stroma in a mouse model of lung
cancer-derived bone metastasis [51]. Highly metastatic human
lung cancer cells (HARA-b) were injected into the left cardiacTable 2
Summary of in vivo studies reporting involvement of macrophages in bone metastasis.
Model Mechanism
Studies investigating effects of macrophage depletion
Intracardiac injections of HARA-B human lung cancer
cells in BALB/c nude mice
Depletion of macrophages by
injections of clodronate-lipos
Clodlip: 400 μl every 3 days
Intratibial injection of human prostate cancer PC-3MM2
cells transfected with lentivirus containing IL-6 small
hairpin RNA (shRNA) or non speciﬁc RNA in NCL-nu
mice
Silencing of IL-6 expression w
tumour cells combined with
macrophages by clodlip intra
injections
Clodlip: 400 μl every 5 days
starting one day prior to tum
injection
Intracardiac injections of PC-3luc human prostate cancer
cells in SCID mice
Administration of anti-huma
mouse CCL2 antibodies targe
derived and host-derived CC
Studies investigating effects of increasing macrophage numbers
Intracardiac injections of human prostate cancer PC-
3lucCCL2 cells over-expressing the monocyte
chemotactic protein CCL2 in CB-17 SCID mice
CCL2 was over-expressed in
tumour growth in bone mon
7 weeks compared to mock t
controlventricle of nude mice on day 0, and animals divided into four
treatment groups receiving either PBS (control), 200 μl or 400 μl
clodronate-liposome (every 3 days for 6 weeks), or 10 mg/kg
reveromycin A (daily for 6 weeks). Treatment with the highest
dose of clodronate liposomes or with reveromycin A resulted in a
signiﬁcantly reduced incidence of bone metastasis as well a
reduced number of metastatic lesions in the hind limbs. Treatment
with reveromycin A resulted in a marked decrease in the number
of osteoclasts associated with the bone lesions, compared to
control. Clodronate liposomes signiﬁcantly decreased the number
of peripheral monocytes surrounding lung cancer cells and the
accumulation of macrophages in tumours, as well as the number
of osteoclasts in the trabecular bone of the hind limbs. These
results suggest that the inhibitory effect of clodronate-liposome on
bone metastasis can be attributed to both the reduction of
osteoclasts as reduced inﬁltration of macrophages in the meta-
static lesions.
3.1.2. Macrophage derived chemokines involved in bone metastasis
Several lines of evidence indicate an association between
chemokines and increased proliferation, enhanced invasiveness,
increased angiogenesis and recruitment of TAMs in tumour
sites [52]. Fig. 3 shows how such interactions potentially may
contribute to development and progression of bone metastasis.
Chemokines comprise a group of similarly structured small pro-
teins involved in the inﬂammatory responses through their ability
to recruit leucocytes [53]. The location of the ﬁrst two cysteine
residues classiﬁes chemokines into two main subfamilies, CXC and
CC [54]. In tumour progression the expression of speciﬁc chemo-
kines, such as CCL-2 and its receptor CCR2, has been identiﬁed in
different cell types in the tumour microenvironment as well as in
tumour cells [53].
3.1.2.1. Monocyte chemoattractant protein 1 (MCP-1; CCL2). Monocyte
chemo-attractant protein 1 (MCP-1; CCL2) belongs to the CC chemo-
kine group and is involved in the recruitment of inﬂammatory cells
(especially monocytes and macrophages) to sites of inﬂammation,
through activation of the CCR2 receptor [55]. Several reports haveFindings Ref.
subcutaneous
ome (clodlip)
Administration of clodlip caused reduced numbers of
monocytes in peripheral blood and of inﬁltrating
macrophages in tumours compared to control.
Signiﬁcantly reduced incidence of bone metastasis,
number of metastatic lesions in bone, as well as number
of tumour colonies and tumour area in bone in clodlip
treated animals compared to control
[51]
for 6 weeks
ith shRNA in
depletion of
peritoneal
Both transfection of PC-3MM2 cells with IL-6 shRNA and
treatment with clodlip resulted in a signiﬁcant reduction
in the number of TAMs and osteoclasts associated with a
signiﬁcant reduction in bone lysis, tumour size and the
incidence of lymph node metastasis compared to control.
Combining clodlip treatment and silencing of IL-6
expression in tumour cells resulted in the lowest
incidence of lymph node metastasis and bone tumours
[68]
for 5 weeks
our cells
n and anti-
ting cancer-
L2, respectively
Administration of both anti-human and anti-mouse CCL2
antibodies resulted in a signiﬁcant reduction of tibial
tumour burden, 87% and 95% respectively compared with
PBS control group
[58]
PC-3 cells,
itored for up to
ransfected
CCL2 over-expression increased the accumulation of
macrophages in tumours. Statistically signiﬁcant higher
tumour growth rate in bone in PC-3lucCCL2 cell line
compared to control
[57]
Macrophages CXCL10
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Fig. 3. Molecular interactions between tumour cells and macrophages potentially associated with bone metastasis. Cytokine and chemokine interactions contribute to
stimulation of tumour cell proliferation as well as acting as chemoattractants for both macrophage precursors and tumour cells. The ﬁgure shows some examples of how key
factors may interact to increase tumour growth and hence bone metastasis progression.
I. Vasiliadou, I. Holen / Journal of Bone Oncology 2 (2013) 158–166 163demonstrated an important role of MCP-1 in the regulation of
tumour growth via macrophage inﬁltration and activation [56–58].
In a number of tumour types, including breast and prostate cancers
[59–61], elevated serum levels of MCP-1 have been correlated with
advanced disease stages, and hence frequently associated with bone
metastasis. Recent evidence supports that MCP-1 may play a key role
in creating the fertile environment for bone metastasis by increasing
the inﬁltration of TAMs as well as by inﬂuencing osteoblasts and
osteoclasts activity [52]. Various tumour cells have been shown to
secrete increased levels of MCP-1, as well as to express the CCR2
receptor, thereby creating an autocrine/paracrine loop [52].
MCP-1 has been directly implicated in prostate cancer cell
proliferation in vitro [62] and has also been identiﬁed as one of the
main regulators of prostate tumour growth and metastasis [63].
Moreover, inhibition of MCP-1 signiﬁcantly suppressed prostate
tumour growth in vivo and highlighted the involvement of MCP-1
in tumour growth via macrophage inﬁltration and subsequent
angiogenesis [64]. Expression of the MCP-1 receptor, CCR2, is
associated with increasing pathological stages of prostate cancer
[65], elevated MCP-1 serum levels correlates with lymph node
involvement in cervical cancer [59,66] and tumour cell expression
of MCP-1 in squamous cell carcinoma of the oesophagus is linked
to lymph node and distant metastasis [22]. In bladder cancer, high
urinary MCP-1 levels were signiﬁcantly correlated with distant
metastasis [67].
A recent study found that MCP-1 over-expression in tumour
cells resulted in an increased macrophage inﬁltration and
an enhanced growth of PC3 prostate cancer xenografts in vivo.
Tumour cells overexpressing MCP-1 lead to a statistically signiﬁ-
cant higher tumour growth rate in bone compared to control,
suggesting that MCP-1 increases tumour growth and bone metas-
tasis via stimulation of macrophage inﬁltration of the tumour
site [57].
MCP-1 has been shown to play a signiﬁcant role in prostate
cancer-induced osteoclastogenesis in vitro and in vivo [57,61]. In
addition, serum MCP-1 levels are shown to be higher in patientswith bone metastases compared to patients with localised disease
in both prostate and lung cancer [53,61]. Moreover, knockdown of
CCR2 in C4-2B and PC3 prostate cancer cell lines signiﬁcantly
inhibited in vitro cell invasion [61], and knockdown of MCP-1 in
PC-3 cells signiﬁcantly reduced the number of osteoclasts present
as well as inhibited prostate cancer cell growth in bone [61]. These
ﬁndings further support the involvement of MCP-1/CCR2 axis in
prostate cancer bone metastasis [61]. A neutralising antibody
targeting mouse MCP-1 has been used to inhibit MCP-1 in vivo
in an effort to identify its role in the development of bone
metastases of prostate cancer. Animals were treated with 2 mg/
kg anti-mouse CCL2 (C1142) or isotype control antibody (C1322)
prior to intratibial injection of PC-3 or VCaP prostate cancer cells
and then twice weekly for the duration of the study. Animals
receiving the CCL2 antibody had signiﬁcantly smaller tumours and
reduced bone destruction compared to the mice receiving the
isotype control antibody [63]. Taken together there is thus con-
siderable evidence for a role of MCP-1, and hence the macrophages
it attracts, in cancer progression.
3.1.2.2. IL-6. The secretion of IL-1 and TNF-α by macrophages stimu-
lates the production of IL-6 by tumour cells. IL-6 is implicated in a
number of cancer-related processes including tumour cell proli-
feration, apoptosis and bone metastasis formation [68]. Clinically,
elevated serum IL-6 levels correlate with increasing prostate cancer
grade as well as the presence of bone metastases [69]. The role of IL-6
in development of bone metastasis has been studied by injecting the
human PC-3MM2 prostate tumour cell line where IL-6 had been
silenced by lentivirus shRNA into the tibias of nude mice. Mice were
treated intraperitoneally with either clodronate-liposome, liposomes
containing PBS, or PBS (every 5 days for 5 weeks). The number
of osteoclasts and TAMs in bone tumours was signiﬁcantly lower in
both the IL-6 shRNA transfected cancer cells and clodronate-liposome
treated group. These reductions correlated with signiﬁcant decreases
in the incidence of lymph node metastasis, bone lysis and tumour
size. The combination of knock-down IL-6 and TAMs reduction
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and bone lesions, further reinforcing the role of TAMs in bone
metastasis [68].
3.1.2.3. CCL-2/IL-6 interactions. CCL-2 is one of the most prevalent
cytokines in the microenvironment of prostate cancer bone
metastases and has a signiﬁcant impact in tumour progression
[52,57,58]. Stimulation of myeloma cells by IL-6 results in CCL2
release [52]. Both IL-6 and CCL-2 are found in high concentration
in tumour microenvironment and when in concert have been
shown to recruit myeloid monocytes and stimulate their differen-
tiation towards M2-type macrophages by inhibition of apoptosis
and autophagy [70]. As already discussed, TAMs of the M2 type
have been shown to be involved in tumour progression and bone
metastasis. The ampliﬁcation loop between IL-6 and CCL2 is
suggested to directly affect malignant cell survival and prolifer-
ation in a paracrine or autocrine fashion [70].
3.1.2.4. CXCL10. CXCL10 belongs to the group of IFNγ-inducible
CXC chemokines and acts via the CXCR3 receptor. CXCL10/CXCR3
interaction has been well established in chronic Th1-inﬂammatory
diseases [71,72]. CXCL10 stimulates the chemotactic migration of
various tumour cells involved in the formation of bone metastasis,
such as mouse B16F10 melanoma cells and human MDA-MB-231
breast cancer cells [71]. However, CXCL10 has contrasting effects
on cancer and stromal cells in the tumour microenvironment,
illustrating the complexity of the metastatic process and the
chemokines involved [71].
A possible explanation of how TAMs promote bone metastasis
via CXCL10/CXCR3 interaction has recently been provided by
studies in a melanoma model where CXCR3 gene silencing in
B16F10 cells inhibited their ability to from bone metastasis
following intra-cardiac injection [71]. Although CXCR3 is a com-
mon receptor for additional IFNγ-inducible CXC chemokines (e.g.
CXCL9 and CXCL11), CXCL10 is highly expressed in bone and hence
is considered the key molecule affected by CXCR3 silencing in this
model. In addition, a similar suppression of bone metastasis was
observed by the use of a neutralising antibody to CXCL10 [71].
Therefore, CXCL10 appears to regulate the formation of bone
metastasis, partly by guiding CXCR3-expressing tumour cells to
the site of metastasis. In this study, production of CXCL10 by
macrophages was stimulated by the direct interaction between
macrophages and breast cancer cells in vitro [71]. The authors
suggest that tumour cells stimulate CXCL10 production by macro-
phages through direct cell–cell contact, and that this in turn
stimulates the progression of osteolytic bone metastasis.
3.1.2.5. Macrophage-stimulating protein (MSP). Macrophage-stimu-
lating protein (MSP) is a serum protein involved in macrophage
accumulation and activation [73,74], initially secreted as an
inactive single-chain precursor (pro-MSP) and activated after
proteolytic cleavage. Pro-MSP is cleaved by membrane-type
protease-1 (MT-SP1, matriptase), a protease expressed on various
types of epithelial cells, as well as on macrophages. The receptor
tyrosine kinase Ron (also known as human MST1R) is the cell
surface receptor for MSP [73], demonstrated to be important in
tumour progression and metastasis [75]. In a mouse model of
breast cancer, investigators have illustrated the role of MSP in
promoting tumour growth and metastasis, including osteolytic
bone metastasis [72]. Overexpression of MSP in MMTV-PyMT
tumours has been correlated to a decreased time to metastasis
as well as to an increased number of metastatic foci (especially to
bone) in vivo. Moreover, overexpression of MSP, MT-SP1, and
MST1R was a strong independent indicator of both metastasis
and death in human breast cancer patients [73]. These ﬁndingssuggest an involvement of MSP in bone metastasis, comple-
menting a recent report that that targeted deletion of the MST1R
kinase domain in the MMTV PyMT model of breast cancer results
in an inhibition in lung metastasis [76]. MSP may potentially
enhance metastasis by interacting with tumour cells and induce
their ability migration, invasion and growth in distant tissues [73],
processes that all involve tumour-associated macrophages.4. Summary and conclusions
Studies using both murine models and human tumours have
provided unequivocal evidence for a role of TAMs in tumour
progression, and potentially in promotion of tumour metastasis,
through regulation of adaptive immunity, stroma remodelling,
basement membrane breakdown and angiogenesis. Although
direct evidence of a speciﬁc role for macrophages in bone
metastasis remains limited, there is accumulating evidence from
in vivo models supporting their involvement. However, it remains
to be determined which stages of the process macrophages
contribute to, in particular their role in early colonisation of bone
compared to the latter stages associated with cancer-induced bone
disease. A major complication encountered in the studies that
have aimed to determine the role of macrophages in bone
metastasis is that the various tools and methods used to modify
the number of macrophages also affect osteoclasts, due to the
similarity in molecular proﬁle and phagocytic capacity between
these closely related cell types. As the osteoclast is established as a
key driver of tumour growth and progression in bone, it has
therefore been impossible to clearly distinguish between the
consequences of macrophage depletion and those mediated by
inhibition of bone resorption.
Further studies of the molecular mechanisms that enable
macrophages to facilitate bone metastasis will improve our under-
standing of the complex microenvironment promoting tumour
progression, thus providing possible therapeutic targets for the
treatment of human bone metastasis.
Macrophages in bonemetastasis –main outstanding questions:1. To what extent can our understanding of the role of macro-
phages obtained in model systems be transferred the human
disease?2. At what stage(s) of bone metastasis are macrophages critically
involved?3. Is the main role of macrophages to support the development of
the metastasis vasculature or are they also involved in other
processes?4. Is there a particular macrophage subtype population and/or
distribution in bone metastases?5. Do macrophages in bone metastasis represent a potential
therapeutic target?6. How are macrophages in bone metastases affected by anti-
cancer therapy?7. Do macrophages in bone metastases modify response to
therapies?8. Are macrophages in bone metastases different from those of
other metastatic foci?9. Is there a speciﬁc role for macrophages in bone metastasis or
are they involved in metastatic disease in general?Conﬂict of interest statement
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